Development of Diagnostic Biomarkers in the Inflammed and Non-Inflamed Intestinal Mucosa of Patients with Crohn's Disease Using Bioinformatics Analysis
Development of Diagnostic Biomarkers in the Inflammed and Non-Inflamed Intestinal Mucosa of Patients with Crohn's Disease Using Bioinformatics Analysis
Mohsen Sheykhhasan,1Azar Sheikholeslami,2Hoda Fazaeli,3Naser Kalhor,4,*
1. Department of Mesenchymal Stem Cells, the Academic Center for Education, Culture and Research, Qom Branch, Qom-Iran. 2. Department of Mesenchymal Stem Cells, the Academic Center for Education, Culture and Research, Qom Branch, Qom-Iran. 3. Department of Mesenchymal Stem Cells, the Academic Center for Education, Culture and Research, Qom Branch, Qom-Iran. 4. Department of Mesenchymal Stem Cells, the Academic Center for Education, Culture and Research, Qom Branch, Qom-Iran.
Introduction: Despite having no known etiology, Crohn's disease (CD), an inflammatory bowel disorder, is frequently associated with genetic, immunological, and environmental variables. In the current work, the postulated molecular pathways in the inflamed and non-inflamed intestinal mucosa are subsequently explained using the transcriptional signatures we uncover in CD patients.
Methods: We have access to the GSE83448 gene expression profiles via the Omnibus gene expression database (GEO, https://www.ncbi.nlm.nih.gov/geo/). We conducted Gene Ontology (GO) keywords and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways searches using the web tool DAVID (https://david.ncifcrf.gov/) to enhance the identification of the biological activities of DEGs. Using the GEO2R instrument, DEGs were found in the inflamed and non-inflamed intestinal mucosa of CD patients as compared to the control group. Using the Cytoscape application, DEG protein-protein interaction (PPI) networks along with significant modules and hub genes were constructed.
Results: Patients' intestinal mucosa was divided into group’s inflamed and non-inflamed intestinal mucosa using the biomarkers connective tissue growth factor (CTGF), matrix metallopeptidase 2 (MMP2), integrin alpha M (ITGAM), cadherin 1 (CDH1), JUN, collagen type I alpha 2 chain (COL1A2), collagen type III alpha 1 chain (COL3A1), C-X-C motif chemokine ligand 8 (CXCL8), serine protease inhibitor clade E member 1 (SERPINE1), and periostin (POSTN).
Conclusion: The development of new molecular targets and diagnostic biomarkers for both inflamed and non-inflamed intestinal mucosa in CD patients may be a result of these findings.